Alpine eyes $100M cap­i­tal in­fu­sion; Bob Dug­gan lends $65M to cos­met­ics com­pa­ny-turned-biotech

Alpine Im­mune Sci­ences is look­ing to reel in $100 mil­lion by Fri­day by sell­ing 13.6 mil­lion shares at $7.35 a pop, the biotech said late Tues­day. Shares $ALPN were down about 6% af­ter the open­ing bell Wednes­day.

Like many oth­er biotechs this year, Alpine is look­ing to beef up its cash re­serves af­ter re­leas­ing some da­ta on two drugs at its R&D day last week. The biotech said a Phase I healthy vol­un­teer study sup­port­ed fur­ther de­vel­op­ment of ALPN-303, a BAFF/APRIL an­tag­o­nist for b-cell me­di­at­ed dis­eases.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER